New drug shows promise for rare kidney conditions

NCT ID NCT05083364

First seen Dec 16, 2025 · Last updated Jun 15, 2026 · Updated 31 times

Summary

This study tested an experimental drug called ARO-C3 in 62 healthy adults and patients with kidney diseases caused by an overactive immune system (C3 glomerulopathy and IgA nephropathy). The goal was to see if the drug is safe and how the body processes it. Participants received one or more doses, and the results will help decide future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Auckland, 1010, New Zealand

  • Research Site 1

    Camperdown, New South Wales, 2050, Australia

  • Research Site 1

    Gamcheon, Busan, 49267, South Korea

  • Research Site 2

    Clayton, Victoria, 3168, Australia

  • Research Site 2

    Tbilisi, 0112, Georgia

  • Research Site 2

    Cologne, 50937, Germany

  • Research Site 2

    Haeundae, Busan, 48108, South Korea

  • Research Site 2

    Bangkok, 10400, Thailand

  • Research Site 3

    Concord, New South Wales, 2139, Australia

  • Research Site 3

    Daegu, 42601, South Korea

  • Research Site 3

    Chiang Mai, 50200, Thailand

  • Research Site 4

    Erlangen, 91054, Germany

  • Research Site 4

    Goyang-si, Gyeonggi-do, 10444, South Korea

  • Research Site 4

    Oxford, OX3 7LE, United Kingdom

  • Research Site 6

    Soeul, 03722, South Korea

  • Research Site 8

    Soeul, 05030, South Korea

Conditions

Explore the condition pages connected to this study.